Oct 2026· Cancers· Vol 18· 0 citations· 24 references
Medicine
TL;DR
There is currently no evidence regarding the extent to which bone metastases affect the incidence of side effects during pemetrexed therapy, and patients with lung adenocarcinoma might benefit from a treatment regimen without pemetrexed or from closer monitoring during therapy, in line with a personalized treatment approach.
Abstract
Simple Summary Despite years of use, there is currently no evidence regarding the extent to which bone metastases affect the incidence of side effects during pemetrexed therapy. Based on clinical observations, a retrospective study was conducted to investigate the incidence of severe hematopoietic side effects in patients with lung adenocarcinoma in order to identify patients at risk for these events. In the future, these patients might benefit from a treatment regimen without pemetrexed or from closer monitoring during therapy, in line with a personalized treatment approach.
It is suggested that treatment-emergent skin toxic effects may serve as an early clinical marker of treatment benefit in patients receiving first-line enfortumab vedotin plus pembrolizumab and warrant prospective validation.
Zachariah Thomas, Cindy Y. Jiang, Patrick Speck et al.· JAMA Network Open· 0 citations
Treatment opportunities using the enfortumab vedotin plus pembrolizumab (EV+P) combination are expanding for patients with unresectable or metastatic urothelial carcinoma. We report the case of a 93-year-old man with bladder cancer and lung metastases who received EV+P therapy and achieved a complete response. By omitt...
Kazumasa Jojima, A. Minato, Yuto Tsubonuma et al.· Urologia internationalis· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD) is commonly diagnosed in patients with metastatic breast cancer (mBC). Poly(ADP-ribose)polymerase inhibitors (PARPi) improve outcomes in BRCA-mutated mBC by blocking DNA-repair mechanisms. Preclinical studies suggest that PARPi may also benefit MASLD by r...
M. Gion, Diego Burgos-Santamaría, Luis Téllez et al.· npj Gut and Liver· 0 citations
Simple Summary This retrospective study evaluated the effectiveness and safety of adding a programmed death-ligand 1 (PD-L1) inhibitor to platinum-based chemotherapy in patients aged ≥75 year with extensive-stage small cell lung cancer. The combination treatment significantly prolonged overall survival compared with ch...
Minoru Kobayashi, Satoshi Watanabe, S. Hirose et al.· Cancers· 0 citations
Abstract Introduction Cutaneous angiosarcoma (cAS) is a rare and aggressive malignancy with a poor prognosis. The disease most commonly occurs in older adults, with a peak age of 79–85 years and its incidence is expected to increase with population ageing. Standard treatments include radical surgery, radiation therapy,...
D. Ogata, E. Nakano, N. Yamazaki et al.· BMJ Open· 0 citations
Background Pembrolizumab–lenvatinib (P/L) is a standard option for patients with advanced or metastatic endometrial cancer (a/m EC) progressing after platinum-based chemotherapy, based on the KEYNOTE-775 trial. However, concerns remain regarding its real-world applicability, particularly in older, frailer patients and...
D. B. Roufai, L. Mansi, M. H. Diallo et al.· ESMO Open· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
